WNV Treatment Protocol: Blood Pressure Drugs (2)

[1]
From: David W. Moskowitz, MD, MA (Oxon.), FACP

I'm having difficulty getting out the word about our free nation-wide
clinical trial for West Nile virus encephalitis, and would therefore
like to bring it to the attention of public health officials so they
can let their local medical community know about it.

There is no expense to this trial, other than the cost of the blood
pressure pills themselves (about $1 a pill a day). GenoMed supplies
the protocol, which is patent-pending. We use existing, safe, already
FDA-approved drugs currently being used to treat high blood pressure
for this new disease indication.

The only "side-effect," blood pressure lowering, can be minimized by
using a tiny dose of the blood pressure pill.

To enroll, a patient simply needs to click on "West Nile trial" at
our home page, www.genomedics.com. They'll be asked for their email
address, so that we can follow up with them during the summer. Then
they'll be able to download the trial documents to share with their
physician. Their physician will serve as the patient's "IRB"--a
disinterested, knowledgeable third party who will decide whether the
trial is in the best interests of his/her patient.

Because of our 100% success rate so far among immunocompetent
patients (n=12), we don't feel that it's ethical to randomize
patients to receive a placebo control.

Contemporary and historical untreated controls will be used as
comparison groups instead.

Thank you very much.
Sincerely yours,
Dave Moskowitz MD

David W. Moskowitz, MD, MA (Oxon.), FACP
Chairman, CEO and Chief Medical Officer
GenoMed, Inc.
website: www.genomedics.com
ticker symbol: GMED (on OTC Pinksheets)
Address:
909 S. Taylor Ave.
St. Louis, MO 63110
tel. 314-977-0110 (soon changing to 314-652-0502)
FAX 314-754-9772
email: dwmoskowitz@genomedics.com

[2]
To put Dr. Moskowitz's request into context, a Press Release
regarding the trial is pasted below. It was previously posted on
this listserv Apr 30, 2004:

GenoMed's Treatment Showing 100% Response Rate Among Immunocompetent
Patients; Nationwide Trial Gaining Momentum

CONTACT: GenoMed Inc.
David W. Moskowitz, MD, MA, FACP
(314) 977-0115
dwmoskowitz@genomedics.com

ST. LOUIS, MO. April 23, 2004. GenoMed, Inc., a Next Generation
Disease Management™ company that uses its expertise in genomics to
improve patient outcomes, said today that it will be limiting its
treatment for West Nile virus encephalitis to immunocompetent
patients only, where it has posted a 100% success rate.

Ten out of ten patients, including 4 over the age of 70, responded
completely to GenoMed's treatment. The only failure since late
August, 2003 when the trial began was a young woman with chronic
leukemia treated last September.

So far this April, 31 people have downloaded GenoMed's West Nile
virus trial document. These include 4 physicians; 3 public health
officers, including one from Manitoba, Canada and one from Arizona; 2
people from blood banks and 2 more from hospitals.
In addition, 6 patients with chronic residual disease after getting
West Nile virus encephalitis last summer have signed up for GenoMed's
trial. One patient with right leg paralysis who has been on GenoMed's
treatment during the winter has recovered nearly complete function of
his right leg.

GenoMed's patent-pending protocol uses blood-pressure drugs that are
safe and already familiar to most physicians. They're carried in
every drug store. The protocol, developed by Dr. David Moskowitz, the
Company’s Chairman, CEO and Chief Medical Officer, is based on the
theory that brain inflammation and death result from an over-response
by the patient’s immune system to the West Nile virus. GenoMed’s
protocol gently suppresses the immune system at an early step in its
activation. The results of Dr. Moskowitz’s first eight patients will
be published soon in a peer-reviewed medical journal.

If GenoMed's current 100% cure rate for patients who aren't
immunosuppressed holds up, GenoMed hopes to prevent all deaths and
cases of paralysis from West Nile virus encephalitis this season.
Immunosuppressed patients include those with AIDS, those taking
chemotherapy for cancer, and organ transplant recipients. GenoMed's
treatment approach is already known not to work for this group.

For the general population, GenoMed recommends beginning its
treatment protocol once a person develops fever and flu-like symptoms
after a mosquito bite.

GenoMed hopes to eliminate the threat of West Nile virus from the
general population on the 50th anniversary of the famous 1954 polio
field trials which ended the threat of polio in the U.S. For more
information, click on the "West Nile trial" button at
http://www.genomedics.com.

Dr. Moskowitz is a Harvard- and Oxford-educated physician, who
trained for seven years in Internal Medicine, Biochemistry, and
Nephrology at Washington University School of Medicine in St. Louis
before spending 11 years on the faculty of St. Louis University
School of Medicine. He is a noted pioneer in the field of medical
genomics, and has been recognized for his groundbreaking treatment of
diseases associated with the angiotensin I-converting enzyme, such as
chronic renal failure due to hypertension or type II diabetes. Dr.
Moskowitz’s research on viruses, including West Nile virus, avian
influenza ("bird flu"), and SARS, are regarded as innovative
approaches for otherwise incurable diseases.
About GenoMed

GenoMed is leading the medical revolution which medical genomics has
already made possible. GenoMed is a Next Generation Disease
ManagementTM company whose mission is to improve patient outcomes by
identifying the genetic pathways that cause disease. This summer the
Company is conducting a nationwide free clinical trial for West Nile
virus encephalitis which will be published before the 2005 West Nile
virus season begins. If the Company's protocol continues to be
successful, GenoMed will market it in 2005. GenoMed is currently
marketing its protocol for delaying complications such as kidney
failure of common diseases like high blood pressure and diabetes,
which affect 80 million Americans, and emphysema, which affects
another 3 million people in the U.S.
Safe Harbor Statement

This press release contains forward looking statements, including
those statements pertaining to GenoMed, Inc. finances and treatments.
The words or phrases 'ought to' 'should,' 'could,' 'may,' or similar
expressions are intended to identify 'forward-looking statements'
within the meaning of the Private Securities Litigation Reform Act of
1995. Actual results could differ materially from those projected in
the forward looking statements as a result of a number of risks and
uncertainties, including but not limited to: (a) whether our
treatment for West Nile virus encephalitis continues to be as
effective as it has been so far; (b) whether our server holds up to
global demand; (c) our research and development being subject to
other economic, regulatory, governmental, and technological factors.
Statements made herein are as of the date of this press release and
should not be relied upon as of any subsequent date. Unless otherwise
required by applicable law, we specifically disclaim any obligation
to update any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date of
such statement.

--
-------------------------------------------------------------------------------------------
WESTNILEVIRUS-L is an email discussion group for communication
and discussion about West Nile Virus, particularly regarding policy,
risk reduction and public education issues. It is moderated by
Dr. Lois Levitan, Program Leader of the Cornell University
Environmental Risk Analysis Program (ERAP).
To subscribe (or unsubscribe), send an email request with your name
and contact information to <envrisk@cornell.edu>.
To receive messages once a day in digest format,  subscribers can
send an email to <listproc@cornell.edu> with message:
"set WESTNILEVIRUS-L mail digest-nomime".
Subscribers are encouraged to post to the group by sending
messages to <envrisk@cornell.edu>.  Please put "WNV Listserv" in
the subject line and send only unformatted text, without attachments.
---------------------------------------------------------------------------------------------